within Pharmacolibrary.Drugs.ATC.D;

model D06BB08
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D06BB08</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ibacitabine is a nucleoside analogue with antiviral properties, primarily developed for topical use in the treatment of herpes simplex infections of the skin. It is not currently approved for medical use and is largely of historical research interest.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult human topical application, as no primary PK publications exist for ibacitabine.</p><h4>References</h4><ol><li><p>Koch, SA, &amp; Sloan, KB (1987). N-Mannich-base prodrugs of 5-iodo-2&#x27;-deoxycytidine as topical delivery enhancers. <i>Pharmaceutical research</i> 4(4) 317–320. DOI:<a href=\"https://doi.org/10.1023/a:1016497204211\">10.1023/a:1016497204211</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3508538/\">https://pubmed.ncbi.nlm.nih.gov/3508538</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D06BB08;
